Holen Sie sich die Stockscreener-App
0.724
41.03%
-0.446
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.17
Offen:
$0.735
24-Stunden-Volumen:
10,485
Relative Volume:
87.22
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.63M
KGV:
-1.6837
EPS:
-0.43
Netto-Cashflow:
$-21.84M
1W Leistung:
-41.03%
1M Leistung:
-43.90%
6M Leistung:
-68.49%
1J Leistung:
-87.10%
1-Tages-Spanne:
$0.7236
$0.75
1-Wochen-Bereich:
$0.7236
$0.75
52-Wochen-Spanne:
$0.7236
$0.75
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Firmenname
Brainstorm Cell Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BCLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.7282 | 0 | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.88 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.70 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.17 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
599.68 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.00 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-11-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-12-19 | Bestätigt | Maxim Group | Buy |
| 2015-12-22 | Bestätigt | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
Sector Leaders Rotate Capital Into Brainstorm Cell Therapeutics Inc.Weekly Top Gainers Forecast Watchlist Released - metal.it
Why is Brainstorm Cell Therapeutics Inc. stock attracting strong analyst attentionChart Pattern Opportunities With High Returns - jammulinksnews.com
What are Brainstorm Cell Therapeutics Inc. company’s key revenue driversAdvanced Screener Growth Plan For Fast Growth - jammulinksnews.com
Does Brainstorm Cell Therapeutics Inc. stock perform well during market downturnsUnlock powerful stock screening techniques - jammulinksnews.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting And Transition To OTCQB - Barchart.com
Is Brainstorm Cell Therapeutics Inc. stock overvalued or undervaluedInvest smarter with daily market updates - jammulinksnews.com
What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyHigh Win Rate Stock Ideas - metal.it
What analysts say about Brainstorm Cell Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
What drives Brainstorm Cell Therapeutics Inc. stock priceRapid capital growth - PrintWeekIndia
What risks could impact Brainstorm Cell Therapeutics Inc. stock performanceMarket-beating performance - jammulinksnews.com
Is Brainstorm Cell Therapeutics Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
How Brainstorm Cell Therapeutics Inc. stock reacts to Fed policy changesAccelerated financial growth - jammulinksnews.com
BrainStorm Cell Therapeutics Downgraded to Hold by Maxim Group - AInvest
Maxim Group Downgrades Brainstorm Cell Therapeutics(BCLI.US) to Hold Rating, Raises Target Price to $6.6 - 富途牛牛
Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits
Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - inkl
Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb - TradingView
Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks
Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener
BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest
BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - WV News
BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com
Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser
How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa
Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Brainstorm Cell Therapeutics Inc-Aktie (BCLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
1.65%
0.57%
Kapitalisierung:
|
Volumen (24h):